AAPL   377.32 (-1.20%)
MSFT   203.32 (-1.81%)
FB   233.05 (-2.49%)
NVDA   394.82 (-1.81%)
CGC   16.98 (-1.85%)
BABA   242.31 (-3.72%)
TSLA   1,460.62 (-2.43%)
AMD   52.52 (-2.00%)
GILD   75.61 (-1.40%)
DIS   115.49 (-0.65%)
NFLX   502.27 (-4.42%)
AAPL   377.32 (-1.20%)
MSFT   203.32 (-1.81%)
FB   233.05 (-2.49%)
NVDA   394.82 (-1.81%)
CGC   16.98 (-1.85%)
BABA   242.31 (-3.72%)
TSLA   1,460.62 (-2.43%)
AMD   52.52 (-2.00%)
GILD   75.61 (-1.40%)
DIS   115.49 (-0.65%)
NFLX   502.27 (-4.42%)
AAPL   377.32 (-1.20%)
MSFT   203.32 (-1.81%)
FB   233.05 (-2.49%)
NVDA   394.82 (-1.81%)
CGC   16.98 (-1.85%)
BABA   242.31 (-3.72%)
TSLA   1,460.62 (-2.43%)
AMD   52.52 (-2.00%)
GILD   75.61 (-1.40%)
DIS   115.49 (-0.65%)
NFLX   502.27 (-4.42%)
AAPL   377.32 (-1.20%)
MSFT   203.32 (-1.81%)
FB   233.05 (-2.49%)
NVDA   394.82 (-1.81%)
CGC   16.98 (-1.85%)
BABA   242.31 (-3.72%)
TSLA   1,460.62 (-2.43%)
AMD   52.52 (-2.00%)
GILD   75.61 (-1.40%)
DIS   115.49 (-0.65%)
NFLX   502.27 (-4.42%)
Log in

NASDAQ:VRNAVERONA PHARMA P/S Stock Price, Forecast & News

$4.74
+0.03 (+0.64 %)
(As of 07/14/2020 10:08 AM ET)
Add
Compare
Today's Range
$4.51
Now: $4.75
$4.75
50-Day Range
$4.25
MA: $4.93
$5.76
52-Week Range
$2.01
Now: $4.75
$12.89
Volume837 shs
Average Volume24,849 shs
Market Capitalization$62.49 million
P/E RatioN/A
Dividend YieldN/A
Beta0.1
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Read More
VERONA PHARMA P/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRNA
CUSIPN/A
Phone44-20-3283-4200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.28 per share

Profitability

Net Income$-40,780,000.00

Miscellaneous

Employees22
Market Cap$62.49 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive VRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.

VERONA PHARMA P/S (NASDAQ:VRNA) Frequently Asked Questions

How has VERONA PHARMA P/S's stock been impacted by COVID-19 (Coronavirus)?

VERONA PHARMA P/S's stock was trading at $4.84 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VRNA stock has decreased by 2.0% and is now trading at $4.7450. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of VERONA PHARMA P/S?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VERONA PHARMA P/S in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for VERONA PHARMA P/S.

When is VERONA PHARMA P/S's next earnings date?

VERONA PHARMA P/S is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for VERONA PHARMA P/S.

How were VERONA PHARMA P/S's earnings last quarter?

VERONA PHARMA P/S (NASDAQ:VRNA) issued its quarterly earnings data on Thursday, April, 30th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.34. View VERONA PHARMA P/S's earnings history.

What price target have analysts set for VRNA?

2 equities research analysts have issued twelve-month price targets for VERONA PHARMA P/S's shares. Their forecasts range from $34.00 to $50.00. On average, they expect VERONA PHARMA P/S's share price to reach $42.00 in the next twelve months. This suggests a possible upside of 785.1% from the stock's current price. View analysts' price targets for VERONA PHARMA P/S.

Has VERONA PHARMA P/S been receiving favorable news coverage?

News articles about VRNA stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. VERONA PHARMA P/S earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about VERONA PHARMA P/S.

Are investors shorting VERONA PHARMA P/S?

VERONA PHARMA P/S saw a increase in short interest in June. As of June 30th, there was short interest totaling 12,300 shares, an increase of 70.8% from the June 15th total of 7,200 shares. Based on an average trading volume of 52,500 shares, the short-interest ratio is presently 0.2 days. Currently, 0.1% of the shares of the stock are short sold. View VERONA PHARMA P/S's Current Options Chain.

Who are some of VERONA PHARMA P/S's key competitors?

What other stocks do shareholders of VERONA PHARMA P/S own?

Who are VERONA PHARMA P/S's key executives?

VERONA PHARMA P/S's management team includes the following people:
  • Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 64)
  • Mr. Piers John Morgan, Chief Financial Officer (Age 53)
  • Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 52)
  • Ms. Victoria Stewart, Director of Communications
  • Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 57)

When did VERONA PHARMA P/S IPO?

(VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

What is VERONA PHARMA P/S's stock symbol?

VERONA PHARMA P/S trades on the NASDAQ under the ticker symbol "VRNA."

How do I buy shares of VERONA PHARMA P/S?

Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is VERONA PHARMA P/S's stock price today?

One share of VRNA stock can currently be purchased for approximately $4.75.

How big of a company is VERONA PHARMA P/S?

VERONA PHARMA P/S has a market capitalization of $62.49 million. The company earns $-40,780,000.00 in net income (profit) each year or ($3.10) on an earnings per share basis. VERONA PHARMA P/S employs 22 workers across the globe.

What is VERONA PHARMA P/S's official website?

The official website for VERONA PHARMA P/S is www.veronapharma.com.

How can I contact VERONA PHARMA P/S?

VERONA PHARMA P/S's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.